FDA Advisory Committee Recommends Emergency Use Authorization of Pfizer COVID-19 Vaccine

A committee of vaccine advisers to the United States Food and Drug Administration (FDA) has recommended the emergency use authorization of the COVID-19 vaccine developed by Pfizer and BioNTech.

A committee of vaccine advisers to the United States Food and Drug Administration (FDA) has recommended the emergency use authorization of the COVID-19 vaccine developed by Pfizer and BioNTech.

The Vaccines and Related Biological Products Advisory Committee, which is responsible for verifying if vaccines are safe for public use, voted 17 to four with one abstention for the emergency approval of the Pfizer/BioNTech COVID-19 vaccine that has already been authorized in the United Kingdom and in Canada.

The recommendation is the final step before the FDA grants the final authorization to widely distribute the first shots around the country that has recorded over 15 million COVID-19 cases, the highest number of cases in the world.

President-elect Joe Biden called the recommendation “a bright light in a needlessly dark time.”

“Our challenge now is to scale up manufacturing and distribution to distribute 100 million shots in the first 100 days of my administration. We are putting together an experienced team to do just that,” Biden said in a statement.

“Before I take office, we need the Trump Administration to purchase the doses it has negotiated with Pfizer and Moderna and to work swiftly to scale manufacturing for the U.S. population,” Biden also said, adding that they need the Congress to fund the distribution.

Pfizer also released a statement, saying that it was “pleased” with the vote.

“If the FDA issues an authorization, stand at the ready to bring this vaccine to people in the U.S. in an effort to help combat this devastating pandemic,” Pfizer Chairman and CEO Dr. Albert Bourla said in a statement.


© Fourth Estate® — All Rights Reserved.
This material may not be published, broadcast, rewritten or redistributed.